Riboflavin associated with antineoplasia agents comprises a cytotoxic agent with expressive reduction of the required pharmaceutical dose
NOVELTY – The riboflavin associated with antineoplasia agents has expressive reduction of the dose of pharmaceutical required to attain the cytotoxic effect. This decreases the side-effects and also the probability of attainment of resistance. USE – In physical chemistry.
Main Application Field
B02 (Fused ring heterocyclics.)
INVENTORS:
FERREIRA CARMEN VERISSIMA
SOUZA ANA CAROLINA SANTOS DE
AOYAMA HIROSHI
QUEIROZ KARLA CRISTINA DE SOUZA
PEPPELENBOSCH MAIKEL PETRUS
89_RIBOFLAVINA
Patent number: BR200505220-A
PATENT STATUS:
For information contact Inova Unicamp
FOR ADDITIONAL INFORMATION:
parcerias@inova.unicamp.br
+55 (19) 3521-5207 / 2607
This technology profile has been automatically generated.